Abstract | BACKGROUND: Although human papillomavirus (HPV) vaccines are highly efficacious in protecting against HPV infections and related diseases, vaccination may trigger replacement by nontargeted genotypes if these compete with the vaccine-targeted types. HPV genotype replacement has been deemed unlikely, based on the lack of systematic increases in the prevalence of nonvaccine-type (NVT) infection in the first decade after vaccination, and on the presence of cross-protection for some NVTs. METHODS: To investigate whether type replacement can be inferred from early postvaccination surveillance, we constructed a transmission model in which a vaccine type and an NVT compete through infection-induced cross-immunity. We simulated scenarios of different levels of cross-immunity and vaccine-induced cross-protection to the NVT. We validated whether commonly used measures correctly indicate type replacement in the long run. RESULTS: Type replacement is a trade-off between cross-immunity and cross-protection; cross-immunity leads to type replacement unless cross-protection is strong enough. With weak cross-protection, NVT prevalence may initially decrease before rebounding into type replacement, exhibiting a honeymoon period. Importantly, vaccine effectiveness for NVTs is inadequate for indicating type replacement. CONCLUSIONS: Although postvaccination surveillance thus far is reassuring, it is still too early to preclude type replacement. Monitoring of NVTs remains pivotal in gauging population-level impacts of HPV vaccination.
|
Authors | Irene Man, Simopekka Vänskä, Matti Lehtinen, Johannes A Bogaards |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 224
Issue 3
Pg. 481-491
(08 02 2021)
ISSN: 1537-6613 [Electronic] United States |
PMID | 31985011
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. |
Chemical References |
|
Topics |
- Alphapapillomavirus
(genetics)
- Genotype
- Humans
- Papillomaviridae
(genetics, immunology)
- Papillomavirus Infections
(epidemiology, prevention & control)
- Papillomavirus Vaccines
- Vaccine Efficacy
|